Shots:

•  The approval from Japanese Ministry of Health is based on two P-III study FRAME &  BRIDGE assessing Evenity (210mg) vs PBO in 7-180 & 245 postmenopausal women with osteoporosis & men with osteoporosis respectively for 12 months
• Evenity (romosozumab) 105mg IV SC is a mAb- indicated for the reduction of    osteoporosis at high risk of fracture in adults- with its MAA filling under review by the US FDA and EMA
• Amgen Astellas’ Evenity has received its first approval worldwide and third for the    company. In 2004- Amgen and UCB collaborated to jointly develop Evenity worldwide

Ref: Amgen Astellas BioPharma| Image: Astellas